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respectively, whereas miR-24 is ubiquitously expressed in all hematopoietic lineages. 5 miR-93 was included because of its previously published use as a housekeeping gene in serum samples. 7 RNA was extracted from 200 ml of serum using Qiagen miRNeasy kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions, because of its superior efficacy and handling compared with other common RNA extraction protocols (results not shown). cDNA synthesis as well as qRT-PCR was performed according to the manufacturer's instructions and all samples were analyzed in triplicate. Mean absolute Ct values and s.d. are displayed on the graphs. Statistics were performed using Student's t-test and Po0.05 was considered as significant.
To assess the effect of short-term storage on miRNA stability, freshly isolated serum from three healthy donors was stored for 10 days at À 80 1C without thawing, at À 80 1C including a daily freeze/ thaw cycle, at À 20 1C without thawing and at room temperature (RT). No difference could be observed between storage at À 80 and À 20 1C (Figure 1a) , whereas storage at RT led to a significant reduction of miRNA levels compared with storage at À 80 1C (P ¼ 0.0017) (Figure 1a) . In contrast to previous reports, 3 repeated freeze and thaw cycles also led to a significant decrease of miRNA levels (P ¼ 0.0079) compared with continuous storage at À 80 1C (Figure 1a) . Quantification of individual miRNAs by qRT-PCR confirmed the Bioanalyzer results (Figure 1b) . Remarkably, all four miRNAs were still detectable after 10 days at RT, highlighting the superior stability of serum miRNAs compared with serum mRNA. 8, 9 Owing to the fact that many institutions store serum samples not uniformly at À 80 1C, we investigated the impact of intermediate-term storage (20 months) at À 20 versus À 80 1C on the abundance of individual miRNAs. Serum from patients with multiple myeloma (MM) was simultaneously frozen at À 20 1C as well as À 80 1C and thawed after 20 months followed by RNA extraction and quantification using the Bioanalyzer small RNA kit (n ¼ 5) and qRT-PCR (n ¼ 3). No significant difference of total RNA concentration was detected (P ¼ 0.97) (Figure 1c) . Out of the four selected miRNAs only miR-93 showed a significant decrease (Po0.04) at À 20 1C (Figure 1d ). These findings suggest differences in the stability of individual serum miRNAs frozen at different time points and temperatures. To further explore this matter, serum miRNAs derived from three MM patient samples, simultaneously frozen at À 20 and À 80 1C for 20 months, were quantified using Serum/Plasma Focus miRNA PCR panels (Exiqon, Copenhagen, Denmark). Of a total of 182 analyzed miRNA probes, only miR-20a* was undetectable in all patient samples. After interplate calibration, 48 miRNA assays were removed from the analysis because of low and inconsistent expression across the samples. Of all analyzed miRNAs, the calculated DCt However, only 27 (17.1%) miRNAs showed a DCt 41 and 14 miRNAs (8.2%) showed a DCt o À 1 (Figure 1e ), potentially indicating that the storage temperature facilitated a release of miRNAs from their protein or exosome-bound form in certain cases. The balanced increase and decrease of individual miRNAs might explain the lack of differences with regards to the overall amount of miRNAs between storage conditions at À 80 and À 20 1C. These findings further highlight the stability of serum miRNAs, suggesting that storage temperature is less relevant than previously assumed for intermediate-term storage (p20 months). However, this data set also shows that several miRNAs are affected by storage conditions. This implies that for the accurate quantification of individual miRNAs, storage conditions should be kept constant within a cohort of samples.
To explore the impact of long-term storage (up to 10 years) at À 20 1C on serum miRNAs, matched samples from three MM patients, seen in our outpatient clinic in 2002, 2004, 2006, 2008 and 2010 , were analyzed with the Bioanalyzer small RNA kit as well as qRT-PCR to assess miRNA integrity. Only a small difference in miRNA levels could be observed after 2 and 4 years of storage time, whereas a significant decrease was detected after 6 years (P ¼ 0.04) and a further decrease after 10 years (P ¼ 0.05; Figure 1f ). Additionally, quantification of four individual miRNAs by qRT-PCR confirmed the Bioanalyzer results (Figure 1g) , showing the complementarity of both approaches.
These findings underline the stability of miRNAs in short-(10 days), intermediate-(p20 months) and long-term storages (p10 years) at À 80 and À 20 1C. To our surprise, storage at À 20 1C barely impacted the overall amount of miRNAs for at least 2-4 years with only minor changes in the levels of individual miRNAs. Taken together, this study further highlights the potential of miRNAs as biomarkers based on their stability in long-term stored samples, even at conditions that are usually considered as incompatible with subsequent analyses of messenger RNA.
SPARC is dispensable for murine hematopoiesis, despite its suspected pathophysiological role in 5q-myelodysplastic syndrome Leukemia (2012) 26, 2416-2419; doi:10.1038/leu.2012.97
All mature blood cell types arise from a limited number of hematopoietic stem cells (HSCs). HSCs sustain hematopoiesis throughout the lifetime of an individual and any insult to them can lead to severe pathologies. Elucidating the molecular mechanisms that govern the maintenance and differentiation of HSCs is critical to understanding their role in hematological pathologies. In a search for novel regulators of HSCs, we selected SPARC (secreted protein acidic and rich in cysteine, also known as Osteonectin and BM40), because it was identified as one of the candidate regulators of HSCs by molecular profiling of differentiating hematopoietic cells in an in vitro model system. 1 Several lines of evidence have also indicated an important role for SPARC in hematopoiesis. In zebrafish, a knockdown of SPARC resulted in lower numbers of circulating blood cells in developing embryos.
2 In a murine model, SPARC deficiency resulted in thrombocytopenia and reduced erythroid colony formation. 3 In humans, SPARC is transcriptionally silenced in acute myeloid leukemia patients and in cell lines with mixed lineage leukemia rearrangements. 4 SPARC maps to the deleted region in 5q-myelodysplastic syndrome (MDS), an HSC disorder. With indications that SPARC may have a role in the hematopoietic system, we aimed to elucidate its role in the regulation of HSCs, as HSCs have not been characterized in the SPARC null mice.
SPARC is a glycoprotein that binds calcium and interacts with members of the extracellular matrix including collagens and thrombospodin. SPARC is expressed in a variety of tissues undergoing rapid turnover and is a major component of the bone. SPARC expression is associated with cell proliferation, migration, changes in morphology, matrix-remodeling and cell-cell interactions, although the precise function of the gene still remains unknown. 5 SPARC knockout mice (SPARC À / À ) are viable and fertile but display a number of abnormalities, including increased deposition of fat, highly contractile skin, alterations in wound healing and an altered response to tumor growth, most severe of which are osteopenia and early onset cataract.
6,7 SPARC À / À mice generated previously by the targeted mutation of exon 6 that completely lacked SPARC mRNA and protein 6 were used in this study to carry out functional assays for HSCs.
Steady state hematopoiesis was unperturbed in SPARC À / À mice as seen by normal peripheral blood counts (Supplementary Table 1 ). A similar observation was made by Barlow et al. 8 using a mouse model carrying a different mutation in SPARC. Also, the bone marrow (BM) of SPARC À / À mice showed normal morphology and cellularity (Supplementary Figure 1) . A thorough
